2009
DOI: 10.1080/14653240902807018
|View full text |Cite
|
Sign up to set email alerts
|

Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
82
0
4

Year Published

2011
2011
2019
2019

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 116 publications
(88 citation statements)
references
References 21 publications
2
82
0
4
Order By: Relevance
“…MSC is a heterogeneous cellular population consisting of mesenchymal stem cells and previous studies showed that the MSC plays important role in supporting hematopoietic stem cells (HSC) engraftment after transplantation [1,2] . Moreover, recent studies support the potential role of MSC as an immune modulator, and MSC play important role in prevention and treatment of graft-versus-host disease (GVHD) [3][4][5][6][7][8][9][10][11][12] . These MSC applied clinically were all in-vitro expanded.…”
Section: Introductionmentioning
confidence: 99%
“…MSC is a heterogeneous cellular population consisting of mesenchymal stem cells and previous studies showed that the MSC plays important role in supporting hematopoietic stem cells (HSC) engraftment after transplantation [1,2] . Moreover, recent studies support the potential role of MSC as an immune modulator, and MSC play important role in prevention and treatment of graft-versus-host disease (GVHD) [3][4][5][6][7][8][9][10][11][12] . These MSC applied clinically were all in-vitro expanded.…”
Section: Introductionmentioning
confidence: 99%
“…16 In adult patients receiving UCBT with coinfusion of third-party donor-mobilized HCs, MSC administration at the time of transplantation had no effect on the kinetics of UCB cell engraftment, as well as on GvHD prevention. 51 Altogether, these data indicate that co-transplantation of HCs and MSCs is safe, while there is still uncertainty about a real efficacy of MSCs on promoting engraftment of donor cells and accelerating the speed of hematological recovery. In particular, in some contexts (such as T-cell-depleted human leukocyte antigen-disparate allograft from a 35,41 the transplantability and sustained engraftment of MSCs in human beings are largely controversial, probably being unusual events.…”
Section: Clinical Trials Of Msc Infusion To Promote Engraftmentmentioning
confidence: 99%
“…15,16,[47][48][49][50][51] Indeed, to date no adverse effects have been registered after MSC administration, although a longer follow-up is necessary to draw definitive conclusions on potential late adverse events. The execution of large, multicenter, randomized clinical trials specifically addressing response to MSC therapy in terms of prevention of graft failure and facilitation/acceleration of hematopoietic recovery, in comparison with conventional treatment modalities, is warranted to show the real value of this approach.…”
Section: Discussionmentioning
confidence: 99%
“…No adverse events were reported with MSC infusion. Two patients in the MSC group developed steroid-refractory grade II acute GVHD, but therapeutic infusion of MSCs resulted in complete resolution of the GVHD (Gonzalo-Daganzo et al 2009 ) .…”
Section: Co-transplantation Of Umbilical Cord Blood Stem Cells and Mementioning
confidence: 99%